01
Phase 3
707K+ Enrolled
Total participants enrolled across all tracked trials — the largest segment in late-stage studies.
Interested?Contact Us →
N
C
T
2
6
0
4
8
AI powered clinical intelligence platform
1,188+ molecules across 40,000+ trials in 17 countries. The intelligence platform for pharma teams that need to move faster than the market.
Key Metrics
AT A GLANCE
A snapshot of what the PHASE-XS dataset covers across phases, indications, and geographies.
02
Oncology
Top Indication
Leukemia, lymphoma, and solid tumors dominate the trial landscape with 40%+ of all studies.
03
mAb
Leading Tech
Monoclonal antibodies represent the dominant technology platform across all phases.
04
92.3%
Adherence Rate
Average patient compliance across all tracked trials — a key indicator of protocol feasibility.
Dataset Scope
Verified · Live Data
40,000+
Clinical Trials
Coverage
- 40,000+ Trials
- 1,188+ Molecules
- 1,178+ Indications
1,188+
Drug Molecules
Trial Phases
- Early Phase 1
- Phase 1 – 4
- Combined Phases
1,178+
Indications
Technologies
- Monoclonal Antibodies
- CAR-T / Cell Therapy
- ADCs & Biosimilars
17
Countries
Regions
- 17 Countries
- US · UK · IN
- EU · APAC · LATAM
02 / Coverage
THERAPEUTIC AREAS
Coverage across oncology, immunology, rare disease, and emerging biologic platforms.
Largest Segment
01Oncology
Largest Segment
Oncology
Leukemia, lymphoma, melanoma, and solid tumors — spanning checkpoint inhibitors, ADCs, and CAR-T therapies.
Sample Distribution
Technology Mix
Monoclonal Ab
1851
Not Specified
380
Checkpoint Inh.
178
Stem Cell
152
Immunotherapy
124
Illustrative sample
02Autoimmune & Inflammation
03Immunology
Autoimmune & Inflammation
Immunology
Monoclonal antibodies and biologics targeting rheumatoid arthritis, lupus, and inflammatory bowel disease.
Orphan Biologics
04Rare Disease
Orphan Biologics
Rare Disease
Gene therapies and enzyme replacements for rare genetic conditions with small patient populations.
Sample Distribution
Trial Phases
Phase 2945
Phase 1820
Phase 3772
Phase 1 / Phase 2310
+ moreIllustrative sample
05Market Access
06Biosimilars
Market Access
Biosimilars
Follow-on biologics entering the US market — tracking approval timelines, pricing, and competitive dynamics.
Preventive Biologics
07Vaccines
Preventive Biologics
Vaccines
mRNA, viral vector, and recombinant protein vaccine platforms across infectious disease trials.
CNS Biologics
08Neurology
CNS Biologics
Neurology
Emerging biologics for multiple sclerosis, Alzheimer's, and neurodegenerative conditions.
Trials Started Over Time
Highlight — 2009 · count: 92
Participants by Phase
Highlight — Phase 2 · value: 75,699
Top Therapeutic Areas
Oncology
1420
Immunology
640
Neurology
410
Rare Disease
310
Cardiovascular
265
Infectious Dis.
210
Illustrative · trial counts by indication
Trials by Country
US45%
UK10%
India10%
Australia7%
Germany6%
France5%
Others17%
Total: 40,200 · Illustrative sample
03 / Platform
WHY PHASE-XS ?
EVIDENCE DRIVEN
Every insight is grounded in real clinical data — 3,049 trials, rigorously sourced and continuously validated.
MOLECULE TO MARKET
Track the full lifecycle from early-phase discovery through approval, pricing, and post-market surveillance.
REAL-TIME SIGNALS
Competitive intelligence across sponsors, technologies, and therapeutic areas — filterable, sortable, actionable.
PRECISION ANALYTICS
Enrollment forecasts, adherence tracking, and pricing intelligence across 1,246 unique molecules and 1,085 indications.
PHASE-XS
Clinical Intelligence
Ready to accelerate your clinical research decisions?
Contact UsA venture ofCoherent Market Insights ↗
40,000+
Clinical Trials
Spanning 17 countries across all major therapeutic areas
24h
Response Time
Our team responds to every inquiry within one business day
1,200+
Insights / Year
Published annually across pharma, biotech & clinical domains
Existing Clientele
Created billion dollars of revenue impact on thousands of clients.
View All Our Clients
CELLTRION
GSK
Credibility & Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
860519526esomar
Individual · 2026
9001:2015
27001:2022
Why Coherent Market Insights?
85-92%
Proof of Authenticity of Data
Incisive insights cutting across sectors, categories, and geographical horizons
73%+
Client Retention Rate
On an average, 73% of our existing clients have resubscribed to our services
24 Hours
Quick Turn-around
Proven expertise of delivering optimized solutions
1200+
Niche Segments
The go-to research solution provider for complex, hard-to-find insights
KEY STATS
1,200+
Insights Published Per Year
4,800+
Consulting Projects Still Now
350+
Analysts and Contract Consultants
5,150+
Clients Worldwide
Discover Our Latest Insights
Market insights across Healthcare, Chemicals, ICT, Semiconductor, Aerospace, Telecom, Consumer Goods, Energy, and Food & Beverages.
Latest Insights© 2026 PHASE-XS. AI Powered Clinical Intelligence Platform.
Data-driven insights. Built with precision.